Engineered immunomodulatory accessory cells improve experimental allogeneic islet transplantation without immunosuppression

Islet transplantation has been established as a viable treatment modality for type 1 diabetes. However, the side effects of the systemic immunosuppression required for patients often outweigh its benefits. Here, we engineer programmed death ligand-1 and cytotoxic T lymphocyte antigen 4 immunoglobuli...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xi, Wang, Kai, Yu, Ming, Velluto, Diana, Hong, Xuechong, Wang, Bo, Chiu, Alan, Melero-Martin, Juan M., Tomei, Alice A., Ma, Minglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307254/
https://www.ncbi.nlm.nih.gov/pubmed/35867788
http://dx.doi.org/10.1126/sciadv.abn0071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307254/
https://www.ncbi.nlm.nih.gov/pubmed/35867788
http://dx.doi.org/10.1126/sciadv.abn0071

Ejemplares similares